Short and sweet;
Zalicus (ZLCS) has a great trade opportunity coming up created by those who took losses on September 10th of this month from the negative Synavive results. After 30 trading days those who took their losses will want to flood back into Zalicus so they do not miss the pipeline opportunity. Prednisporin Phase III start with Sanofi (NYSE:SNY); and the new Exalgo 32mg dosage royalties with Covidien (COV) it should be fun to watch.
The October run-up to the 10th and 11th should make for very exciting days. If you look at 2010 year end investors did the same thing by selling the losses they had for the 2010 calendar year for tax purposes. First of the new year Zalicus exploded and continued its run to over $3.00 per share.
This is a great entry price at .74 cents and great opportunity for an easy gain back over $1.00 +
Zalicus is a bio-tech company focused on Pain and inflammation treatments, currently with 50 million in cash and 126 million shares outstanding.
Disclosure: I am long ZLCS. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.